drugset / Trial / NCT01237977

Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines

NCT01237977 ↗

Phase 3 Completed 314 enrolled Medy-Tox
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the hypothesis that the efficacy and safety of Meditoxin® are not inferior to Botox®'s in the treatment of glabellar lines.

Timeline

Start
2009-11-23
Primary completion
2010-08-30
Completion
2010-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 20 iu Other

Indications